JP2023536883A5 - - Google Patents
Info
- Publication number
- JP2023536883A5 JP2023536883A5 JP2023507428A JP2023507428A JP2023536883A5 JP 2023536883 A5 JP2023536883 A5 JP 2023536883A5 JP 2023507428 A JP2023507428 A JP 2023507428A JP 2023507428 A JP2023507428 A JP 2023507428A JP 2023536883 A5 JP2023536883 A5 JP 2023536883A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- concentration
- aav particles
- pharmaceutical composition
- poloxamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063128P | 2020-08-07 | 2020-08-07 | |
| US202063063108P | 2020-08-07 | 2020-08-07 | |
| US63/063,128 | 2020-08-07 | ||
| US63/063,108 | 2020-08-07 | ||
| PCT/US2021/044955 WO2022032104A1 (en) | 2020-08-07 | 2021-08-06 | Formulations for highly purified viral particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536883A JP2023536883A (ja) | 2023-08-30 |
| JP2023536883A5 true JP2023536883A5 (cg-RX-API-DMAC7.html) | 2024-08-14 |
Family
ID=80114720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507428A Pending JP2023536883A (ja) | 2020-08-07 | 2021-08-06 | 高度に精製されたウイルス粒子のための製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220040305A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192437A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023536883A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230049670A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116323925A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021320395A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190596A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300323A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001411A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022032104A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096867A (zh) * | 2020-06-02 | 2023-05-09 | 詹森生物科技公司 | 用于病毒纯化的材料和方法 |
| US20230090654A1 (en) * | 2021-08-24 | 2023-03-23 | Homology Medicines, Inc. | Adeno-associated virus formulations |
| CN120603600A (zh) * | 2023-01-19 | 2025-09-05 | 优尼科生物制药有限公司 | 基因递送媒介物的药物配制品 |
| KR20260019635A (ko) * | 2023-06-09 | 2026-02-10 | 사르토리우스 비아이에이 세퍼레이션스 디.오.오. | 완전 충전 아데노 관련 바이러스 (aav) 캡시드의 향상된 분리 방법 |
| WO2025045082A1 (zh) * | 2023-09-01 | 2025-03-06 | 康霖生物科技(杭州)有限公司 | 一种缓冲系统及其相应液体制剂及其用途 |
| CN122580434A (zh) * | 2023-11-30 | 2026-08-14 | 优尼科生物制药有限公司 | 用于病毒药物产品的配制品 |
| CN118957152B (zh) * | 2024-08-30 | 2025-11-25 | 浙江恒驭生物科技有限公司 | 一种腺相关病毒载体基因组滴度检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048005A1 (en) * | 1997-04-24 | 1998-10-29 | University Of Washington | Targeted gene modification by parvoviral vectors |
| US6156303A (en) * | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| EP2420247A1 (en) * | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| ES2932278T3 (es) * | 2004-06-01 | 2023-01-17 | Genzyme Corp | Composiciones y métodos para prevenir la agregación del vector AAV |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| KR102799163B1 (ko) * | 2015-09-17 | 2025-04-21 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Galgt2 유전자 치료 방법 및 물질 |
| US11015174B2 (en) * | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV8 |
| TW201837170A (zh) * | 2017-02-28 | 2018-10-16 | 賓州大學委員會 | 新穎aav媒介的流感疫苗 |
| IL319002A (en) * | 2018-06-14 | 2025-04-01 | Regenxbio Inc | Anion exchange chromatography for recombinant AAV production |
| WO2020023612A1 (en) * | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| JP7630443B2 (ja) * | 2019-04-19 | 2025-02-17 | レジェンクスバイオ インコーポレーテッド | アデノ随伴ウイルスベクター製剤及び方法 |
-
2021
- 2021-08-06 WO PCT/US2021/044955 patent/WO2022032104A1/en not_active Ceased
- 2021-08-06 CN CN202180067655.9A patent/CN116323925A/zh active Pending
- 2021-08-06 IL IL300323A patent/IL300323A/en unknown
- 2021-08-06 US US17/396,090 patent/US20220040305A1/en not_active Abandoned
- 2021-08-06 EP EP21853878.3A patent/EP4192437A4/en active Pending
- 2021-08-06 CA CA3190596A patent/CA3190596A1/en active Pending
- 2021-08-06 JP JP2023507428A patent/JP2023536883A/ja active Pending
- 2021-08-06 AU AU2021320395A patent/AU2021320395A1/en not_active Abandoned
- 2021-08-06 MX MX2023001411A patent/MX2023001411A/es unknown
- 2021-08-06 KR KR1020237007796A patent/KR20230049670A/ko not_active Withdrawn
-
2025
- 2025-11-04 US US19/379,616 patent/US20260061059A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7531654B2 (ja) | アデノ随伴ウイルス精製方法 | |
| US12351832B2 (en) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography | |
| JP7539420B2 (ja) | アデノ随伴ウイルスの精製方法 | |
| US20210324343A1 (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| JP5268890B2 (ja) | Aavの規模適応性の製造方法 | |
| JP2021087431A5 (cg-RX-API-DMAC7.html) | ||
| JP2021530548A5 (cg-RX-API-DMAC7.html) | ||
| JP2022516283A5 (cg-RX-API-DMAC7.html) | ||
| JP2022549380A5 (cg-RX-API-DMAC7.html) | ||
| JP2022547197A5 (cg-RX-API-DMAC7.html) | ||
| CN113993552A (zh) | 腺相关病毒载体制剂和方法 | |
| JP2022533448A5 (cg-RX-API-DMAC7.html) | ||
| RU2785661C2 (ru) | Способы очистки аденоассоциированных вирусов | |
| CA2975569C (en) | Recombinant adeno-associated virus particle purification comprising an affinity purification step | |
| HK1227436A (en) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography | |
| HK1227436A1 (en) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |